Advertisement
Finance
Subscribe to Finance

The Lead

Photo of the Day - HIV Drug Protests in Peru

January 22, 2015 3:14 pm | by Mike Auerbach, Editor In Chief | News | Comments

In Peru, BMS' atazanavir is available as a second-line HIV drug, but its high price is out of reach of many Peruvians with HIV/AIDS.                     

Senator Warren to File Bill Targeting Top Pharma Companies

January 22, 2015 2:24 pm | by STEVE LeBLANC, Associated Press | News | Comments

Warren's bill would require that whenever drug companies enter into a settlement with the...

Treatment Market for Irritable Bowel Syndrome Could Hit $1.5B by 2023, says GlobalData

January 22, 2015 9:11 am | News | Comments

The global therapeutics market for Irritable Bowel Syndrome (IBS) is set to rise in value from $...

Fitch: SCOTUS Extends Patent Benefit for Teva; Generics Lose for Now

January 22, 2015 8:20 am | News | Comments

The Supreme Court (SCOTUS) decision that a federals appeals court wrongly overturned Teva...

View Sample

FREE Email Newsletter

Johnson & Johnson Tops Fourth Quarter Earnings Expectations

January 21, 2015 8:05 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

The strong dollar and stiff competition for some products squeezed J&J in the fourth quarter and it missed Wall Street expectations for revenue, triggering a rare sell-off of its shares. The world's biggest maker of health care products did edge past profit forecasts and there were other bright spots, including a 10% jump in prescription drug sales and increasing use of medical care in the U.S.

Aetna Picks Gilead Sciences Hepatitis C Drugs Over AbbVie's

January 19, 2015 9:43 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Aetna has reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment. The amount of the discount wasn't disclosed.      

Johnson & Johnson Ebola Groups Get $117M in Funding

January 19, 2015 9:37 am | News | Comments

Johnson & Johnson is working with a slew of organizations to speed up development of an Ebola vaccine, and the company said Friday that a European health organization awarded them $117 million.         

Advertisement

AMRI Receives NIH Contract Award

January 19, 2015 9:29 am | News | Comments

AMRI has received a 10-year federal contract award from the NIH for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program, which is a component of the Blueprint Neurotherapeutics Network. AMRI has supported the NIH BPN since 2011, providing chemistry services and discovery technologies.

Evotec Achieves Milestones in TargetAD Collaboration With Janssen

January 15, 2015 2:31 pm | News | Comments

Evotec AG has announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process.

Moderna and Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

January 15, 2015 1:32 pm | News | Comments

Moderna Therapeutics has announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).     

Obama to Renew Push for Paid Leave for Working Parents

January 15, 2015 11:35 am | by DARLENE SUPERVILLE, Associated Press | News | Comments

Renewing a push for paid leave for workers, President Barack Obama will call on Congress, states and cities to pass measures to allow tens of millions of workers to earn up to a week of paid sick time a year, the White House said.    

Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules

January 15, 2015 11:07 am | News | Comments

Elite Pharmaceuticals has announced the first shipments of generic Isradipine 2.5 mg and 5.0 mg capsules. Isradipine is a calcium channel blocker prescribed for hypertension.             

Advertisement

Analyst: Shire Completes ‘Robust’ Deal in $5.2 Billion NPS Pharmaceuticals Acquisition

January 15, 2015 10:55 am | News | Comments

Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData. 

Dendreon Announces Strong Commercial Start to 2015

January 14, 2015 4:13 pm | News | Comments

Dendreon Corporation today announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in the fourth quarter (adjusted for non-recurring items), starting 2015 on a strong footing.

US Job Openings at Fourteen-Year High

January 14, 2015 8:10 am | by CHRISTOPHER S. RUGABER, AP Economics Writer | News | Comments

U.S. employers advertised the most job openings in nearly 14 years in November, the Labor Department said Tuesday. That suggests businesses are determined to keep adding staff because they are confident strong economic growth will create more demand for their goods and services.

Roche, Meiji and Fedora to Collaborate on New Antibiotic to Fight Increasing Bacterial Resistance

January 13, 2015 11:26 am | News | Comments

Roche, Meiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Under the agreement, Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights.

GlobalData: Rheumatoid Arthritis Treatment Market to be Transformed by Novel Drug and Biosimilar Launches

January 13, 2015 11:03 am | News | Comments

The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData. 

Advertisement

Pharmacyclics Reports Good Revenue from Imbruvica

January 13, 2015 9:38 am | by The Associated Press | News | Comments

Shares of Pharmacyclics jumped Tuesday morning after the cancer treatment developer announced better-than-expected revenue forecasts for Imbruvica, a leukemia drug it sells with a Johnson & Johnson subsidiary.      

Johnson & Johnson Licenses Vedanta's Bowel Disease Drug

January 13, 2015 8:31 am | News | Comments

Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.         

Merck Races Bristol-Myers Squibb as it Seeks New OK for Cancer Drug

January 13, 2015 8:22 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer.          

2015 Critical Issues

January 12, 2015 3:57 pm | by Mike Auerbach, Editor In Chief | Blogs | Comments

The pharmaceutical industry faces numerous issues on a day-to-day and yearly basis. Manufacturing, quality control, efficiences, budgets and regulations all must be met or exceeded. Here are ten industry critical issues, I feel the industry will be facing in the coming year.

Perrigo Partners with Ferrara Candy to Enter Gummy Vitamins And Dietary Supplement Market

January 12, 2015 8:38 am | News | Comments

Perrigo Company and Ferrara Candy Company announced today that Perrigo's Nutritionals division has signed a supply agreement with Ferrara to manufacture store brand gummy vitamins and dietary supplements to be sold at leading retailers across the United States.

Shire to Pay $5.2B for NPS Pharma

January 12, 2015 8:28 am | by The Associated Press | News | Comments

The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and conditions that typically command much higher price tags than conventional medications. Shire's best-selling drugs currently include the attention deficit disorder drugs Vyvanse and Adderall XR.

Roche Takes Majority Stake in Foundation Medicine for $1.03B

January 12, 2015 8:23 am | News | Comments

Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.        

Merck Provides Update on Strategic Actions to Transform the Company

January 12, 2015 8:20 am | News | Comments

Merck today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth.

AmerisourceBergen to Acquire MWI Veterinary Supply

January 12, 2015 8:10 am | News | Comments

AmerisourceBergen and MWI Veterinary Supply, today announced that they have entered into a definitive merger agreement for AmerisourceBergen to acquire MWI Veterinary Supply (MWI), the leading animal health distribution company in the United States.

Bristol-Myers' Stock Jumps on Opdivo Phase III Trial Results

January 12, 2015 8:03 am | by The Associated Press | News | Comments

Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer. Company shares jumped Monday in premarket trading after the company said Opdivo met the main goal of a late-stage study by demonstrating better overall patient survival.

AbbVie Forecasts Higher 2015 Profit on New Hep C Drug

January 9, 2015 8:24 am | by The Associated Press | News | Comments

AbbVie is forecasting its 2015 profit will jump sharply from last year's, saying it expects "industry-leading growth," driven mainly by sales of its hot new hepatitis C treatment, Viekira.           

Aptuit Sells Two Sites to AMRI

January 9, 2015 8:04 am | News | Comments

Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading